Author

Gabriella Lindergard

Observed names: G Lindergard, G. Lindergard, G. Lindergård, L. A. G. LINDERGARD, Lindergard, Gabriella

Observed institutions: Pennine Acute Hospitals NHS Trust, University of Liverpool, Liverpool School of Tropical Medicine, Cornell University, North Manchester General Hospital, Manchester University NHS Foundation Trust, Renewable Energy Alaska Project, Centre for Immunity, Infection and Evolution, New York State College of Veterinary Medicine, NIHR Great Ormond Street Hospital Biomedical Research Centre, Canadian Critical Care Trials Group, University College London, University of Glasgow, University of Edinburgh

ORCID: 0009-0003-7054-9939

Observed ORCID: 0009-0003-7054-9939

OpenAlex ID: A5048851852

Mapping the human genetic architecture of COVID-19

2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369

Whole-genome sequencing reveals host factors underlying critical COVID-19

2022 · Athanasios Kousathanas, Erola Pairo-Castineira, et al. · Nature · 326

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 224

A subset of group A-like var genes encodes the malaria parasite ligands for binding to human brain endothelial cells

2012 · Antoine Claessens, Yvonne Adams, et al. · Proceedings of the National Academy of Sciences · 223

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

2021 · Hesham Abdelhady, Marwa Abdelrazik, et al. · JAMA · 210

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 146

Alternative polymerase chain reaction method to identify Plasmodium species in human blood samples: the semi-nested multiplex malaria PCR (SnM-PCR)

2002 · J.M. Rubio, R.J. Post, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 137

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 136

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129

A second update on mapping the human genetic architecture of COVID-19

2023 · The COVID-19 Host Genetics Initiative, Leadership, et al. · Nature · 118

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

2023 · Simin Florescu, Delia Stanciu, et al. · JAMA · 63

Intravenous Vitamin C for Patients Hospitalized With COVID-19

2023 · The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Simin Florescu, et al. · JAMA · 53

Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID

2023 · Nicholas A. Scott, Laurence Pearmain, et al. · European Respiratory Journal · 50

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Human infectivity trait in Trypanosoma brucei: stability, heritability and relationship to sra expression

2004 · C. M. R. TURNER, S. McLELLAN, et al. · Parasitology · 34

The Sensitivity of PCR Detection of Cryptosporidium Oocysts in Fecal Samples Using Two DNA Extraction Methods

2003 · Gabriella Lindergard, Daryl V. Nydam, et al. · Molecular Diagnosis · 31

Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV

2022 · Rachel K.Y. Hung, Elizabeth Binns-Roemer, et al. · Kidney International Reports · 29

Infected erythrocytes expressing DC13 PfEMP1 differ from recombinant proteins in EPCR-binding function

2018 · Yvonne Azasi, Gabriella Lindergard, et al. · Proceedings of the National Academy of Sciences · 29

Rates and Predictors of Treatment Failure in Staphylococcus aureus Prosthetic Joint Infections According to Different Management Strategies: A Multinational Cohort Study—The ARTHR-IS Study Group

2022 · Reinaldo Espíndola, Venanzio Vella, et al. · Infectious Diseases and Therapy · 28

Works count: 50

Citation count: 5,273

H-index: 26

I10-index: 40